The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.

AIMS To carry out a systematic review to assess the effectiveness of cannabis extracts and cannabinoids in the management of chronic nonmalignant neuropathic pain. METHODS Electronic database searches were performed using Medline, PubMed, Embase, all evidence-based medicine reviews, and Web of Science, through communication with the Canadian Consortium for the Investigation of Cannabinoids (CCIC), and by searching printed indices from 1950. Terms used were marijuana, marihuana, cannabis, cannabinoids, nabilone, delta- 9-tetrahydrocannabinol, cannabidiol, ajulemic acid, dronabinol, pain, chronic, disease, and neuropathic. Randomized placebo-controlled trials (RCTs) involving cannabis and cannabinoids for the treatment of chronic nonmalignant pain were selected. Outcomes considered were reduction in pain intensity and adverse events. RESULTS Of the 24 studies that examined chronic neuropathic pain, 11 studies were excluded. The 13 included studies were rated using the Jadad Scale to measure bias in pain research. Evaluation of these studies suggested that cannabinoids may provide effective analgesia in chronic neuropathic pain conditions that are refractory to other treatments. CONCLUSION Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. Further high-quality studies are needed to assess the impact of the duration of the treatment as well as the best form of drug delivery.

[1]  W. Notcutt,et al.  A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis , 2013, Journal of Neurology.

[2]  B. Wilsey,et al.  Low-dose vaporized cannabis significantly improves neuropathic pain. , 2013, The journal of pain : official journal of the American Pain Society.

[3]  L. Korngut,et al.  An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain , 2012, PAIN®.

[4]  M. Lynch,et al.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. , 2011, British journal of clinical pharmacology.

[5]  G. Bennett,et al.  Smoked cannabis for chronic neuropathic pain: a randomized controlled trial , 2010, Canadian Medical Association Journal.

[6]  C. Solaro,et al.  Pharmacological Management of Pain in Patients with Multiple Sclerosis , 2010, Drugs.

[7]  J. L. R. Martin,et al.  Systematic review and meta-analysis of cannabis treatment for chronic pain. , 2009, Pain medicine.

[8]  C. Emery,et al.  Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy , 2009, Diabetes Care.

[9]  A. Hohmann,et al.  Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside , 2009, Neurotherapeutics.

[10]  F. Vaida,et al.  Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial , 2009, Neuropsychopharmacology.

[11]  S. Fishman,et al.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. , 2008, The journal of pain : official journal of the American Pain Society.

[12]  P. Robson,et al.  The Medicinal Uses of Cannabis and Cannabinoids , 2008 .

[13]  M. Serpell,et al.  Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study , 2008, BMJ : British Medical Journal.

[14]  T. Nurmikko,et al.  Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial , 2007, PAIN®.

[15]  M. Rowbotham,et al.  Cannabis in painful HIV-associated sensory neuropathy , 2007, Neurology.

[16]  T. Einarson,et al.  Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain , 2007, Current medical research and opinion.

[17]  W. Poewe,et al.  Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain , 2006, Journal of Neurology.

[18]  A. Thompson,et al.  Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  T. Friede,et al.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis , 2005, Neurology.

[20]  R. Birch,et al.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial , 2004, Pain.

[21]  D. Wade,et al.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.

[22]  T. Jensen,et al.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial , 2004, BMJ : British Medical Journal.

[23]  W. Notcutt,et al.  Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies , 2004, Anaesthesia.

[24]  D. Bouhassira,et al.  Are oral cannabinoids safe and effective in refractory neuropathic pain? , 2004, European journal of pain.

[25]  F. Grotenhermen.  Pharmacology of cannabinoids. , 2004, Neuro endocrinology letters.

[26]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial , 2003, The Lancet.

[27]  M. Karst,et al.  Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. , 2003, JAMA.

[28]  D. Wade,et al.  A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms , 2003, Clinical rehabilitation.

[29]  N. Attal,et al.  [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. , 2002, Presse medicale.

[30]  S. Bagshaw,et al.  Medical Efficacy of Cannabinoids and Marijuana: A Comprehensive Review of the Literature , 2002, Journal of palliative care.

[31]  J. Farrar,et al.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale , 2001, PAIN.

[32]  D. Carroll,et al.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review , 2001, BMJ : British Medical Journal.

[33]  D. Carroll,et al.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review , 2001, BMJ : British Medical Journal.

[34]  A. Jacklin,et al.  Pain relief with oral cannabinoids in familial Mediterranean fever , 1997, Anaesthesia.

[35]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[36]  M. I. M. Fontelles,et al.  Role of Cannabinoids in the Management of Neuropathic Pain , 2008 .

[37]  V. Henn,et al.  Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[38]  M. Fitzcharles,et al.  Cannabis for chronic pain: case series and implications for clinicians. , 2002, Pain research & management.

[39]  H. Kalant.  Medicinal use of cannabis: history and current status. , 2001, Pain research & management.